Selpercatinib prior to radioactive iodine for pediatric papillary thyroid carcinoma
Journal of Pediatric Endocrinology and Metabolism · 2024
DOI: 10.1515/jpem-2024-0281 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, 2024. Verfasst von Harvey K Chiu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology, Department of Pediatrics, Mattel Children's Hospital, UCLA Medical Center, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Thyroid Cancer, Papillary, Thyroid Neoplasms, Iodine Radioisotopes, Pyridines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Objectives
We introduced selpercatinib prior to radioactive iodine therapy prior to radioactive iodine therapy (RAI) for pediatric papillary thyroid cancer (PTC) to enhance the tumorical effects of RAI. Case presentation PTC has an excellent prognosis but is commonly associated with local and distant metastases. Successful complete response to the current standard of care, thyroidectomy with lymph node resection and RAI, is achieved in only a small minority of cases with metastases. The direct effect of tyrosine kinase inhibitors (TKIs) on tumor regression has been confirmed in several randomized controlled studies, while the increased RAI uptake has been reported in small case series, but typically TKIs are currently reserved third-line. Selpercatinib is a TKI that specifically has a durable effect in RET-fusion positive malignancies. We describe a 10-year-old Hispanic girl with metastatic PTC treated with total thyroidectomy and extensive lymph node resection. Evaluation for relevant genetic drivers of the malignancy revealed a strong overexpression of the RET tyrosine kinase domain indicative of a RET gene fusion. Selpercatinib 120 mg twice daily given orally was initiated prior to the initial dose of RAI to achieve further tumor regression by a direct cytostatic effect and then secondarily enhancement of RAI uptake. Minimal side effects occurred, specifically intermittent mild skin rashes that resolved. Resolution of distal lung metastases was noted on CT imaging. RAI was then administered 9 months afterward, with ultimately achievement of a low thyroglobulin level 1.0 ng/mL 11 months after RAI.
Conclusions
In conclusion, selpercatinib given prior to the initial dose of adjunctive RAI for RET-fusion positive PTC is a well-tolerated intervention that further reduces tumor burden and potentially enhances the tumorcidal effects of RAI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Endocrinology, Department of Pediatrics, Mattel Children's Hospital, UCLA Medical Center, Los Angeles, CA, USA.
- Division of Hematology Oncology, Department of Pediatrics, UCLA Medical Center, Los Angeles, CA, USA.
- Department of Endocrine Surgery, UCLA Medical Center, Los Angeles, CA, USA.
Zitieren
APA
Chiu, H. K., Nowicki, T. S., Livhits, M. J., Wu, J. X., & Federman, N. (2024). Selpercatinib prior to radioactive iodine for pediatric papillary thyroid carcinoma. Journal of Pediatric Endocrinology and Metabolism. https://doi.org/10.1515/jpem-2024-0281
Vancouver
Chiu HK, Nowicki TS, Livhits MJ, Wu JX, Federman N. Selpercatinib prior to radioactive iodine for pediatric papillary thyroid carcinoma. Journal of Pediatric Endocrinology and Metabolism. 2024. doi:10.1515/jpem-2024-0281
BibTeX
@article{Chiu2024,
author = {Chiu, Harvey K and Nowicki, Theodore S and Livhits, Masha J and Wu, James X and Federman, Noah},
title = {Selpercatinib prior to radioactive iodine for pediatric papillary thyroid carcinoma},
journal = {Journal of Pediatric Endocrinology and Metabolism},
year = {2024},
doi = {10.1515/jpem-2024-0281}
}
EUVIMED